RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025
RxSight (RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has announced it will release its fourth quarter 2024 financial results on February 25, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone at (800) 715-9871 or (646) 307-1963 using conference code 7159871, or listen to the webcast through the company's investor relations website. A recording will be available after the call.
RxSight (RXST), un'azienda di dispositivi medici oftalmici focalizzata su soluzioni di visione personalizzate per pazienti dopo la chirurgia della cataratta, ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre 2024 il 25 febbraio 2025, dopo la chiusura del mercato. L'azienda terrà una conferenza telefonica alle 13:30 PT / 16:30 ET per discutere i risultati. Gli investitori possono partecipare tramite telefono al (800) 715-9871 o (646) 307-1963 utilizzando il codice della conferenza 7159871, oppure ascoltare la diretta attraverso il sito web delle relazioni con gli investitori dell'azienda. Una registrazione sarà disponibile dopo la chiamata.
RxSight (RXST), una empresa de dispositivos médicos oftálmicos centrada en soluciones de visión personalizadas para pacientes post-cirugía de cataratas, ha anunciado que publicará sus resultados financieros del cuarto trimestre de 2024 el 25 de febrero de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a la 1:30 PM PT / 4:30 PM ET para discutir los resultados. Los inversores pueden unirse por teléfono al (800) 715-9871 o (646) 307-1963 utilizando el código de la conferencia 7159871, o escuchar la transmisión a través del sitio web de relaciones con los inversores de la compañía. Se dispondrá de una grabación después de la llamada.
RxSight (RXST)는 백내장 수술 후 환자를 위한 맞춤형 시력 솔루션에 중점을 둔 안과 의료 기기 회사로, 2024년 4분기 재무 결과를 2025년 2월 25일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 결과를 논의하기 위해 오후 1시 30분 PT / 오후 4시 30분 ET에 컨퍼런스 콜을 진행할 예정입니다. 투자자는 전화 (800) 715-9871 또는 (646) 307-1963에 컨퍼런스 코드 7159871을 사용하여 참여하실 수 있으며, 회사의 투자자 관계 웹사이트를 통해 웹캐스트를 들을 수도 있습니다. 통화 후 녹음된 내용이 제공될 것입니다.
RxSight (RXST), une entreprise de dispositifs médicaux ophtalmiques axée sur des solutions de vision personnalisées pour les patients après une chirurgie de la cataracte, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre de 2024 le 25 février 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique à 13h30 PT / 16h30 ET pour discuter des résultats. Les investisseurs peuvent rejoindre par téléphone au (800) 715-9871 ou (646) 307-1963 en utilisant le code de conférence 7159871, ou écouter le webinaire via le site Internet des relations avec les investisseurs de l'entreprise. Un enregistrement sera disponible après l'appel.
RxSight (RXST), ein auf ophthalmologische medizinische Geräte spezialisiertes Unternehmen, das sich auf maßgeschneiderte Seh-Lösungen für Patienten nach einer Kataraktoperation konzentriert, hat bekannt gegeben, dass es seine Finanzergebnisse für das vierte Quartal 2024 am 25. Februar 2025, nach Marktschluss veröffentlichen wird. Das Unternehmen wird um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können telefonisch unter (800) 715-9871 oder (646) 307-1963 mit dem Konferenzcode 7159871 teilnehmen oder über die Website der Investor Relations des Unternehmens der Webcast anhören. Eine Aufzeichnung wird nach dem Anruf verfügbar sein.
- None.
- None.
ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
When will RxSight (RXST) release Q4 2024 earnings?
What time is RxSight's (RXST) Q4 2024 earnings call?
How can investors access RxSight's (RXST) Q4 2024 earnings call?
Will RxSight (RXST) provide a replay of their Q4 2024 earnings call?
